Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Incyte

< Previous 1 2 3 4 5 Next >
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
From Incyte
Via Business Wire
Tickers INCY
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
From Incyte
Via Business Wire
Tickers INCY
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
From Incyte
Via Business Wire
Tickers INCY
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
Tickers INCY REPL
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
From Incyte
Via Business Wire
Tickers INCY
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
From Incyte
Via Business Wire
Tickers INCY
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.